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Despite collection of patient reported outcome (PRO) data in clinical trials of antiepileptic drugs (AEDs), PRO results
are not being routinely reported on European Medicines Agency (EMA) and Food and Drug Administration (FDA)
product labels. This review aimed to evaluate epilepsy-specific PRO instruments against FDA regulatory standards
for supporting label claims. Structured literature searches were conducted in Embase and Medline databases to
identify epilepsy-specific PRO instruments. Only instruments that could potentially be impacted by pharmacological
treatment, were completed by adults and had evidence of some validation work were selected for review. A total
of 26 PROs were reviewed based on criteria developed from the FDA regulatory standards. The ability to meet
these criteria was classified as either full, partial or no evidence, whereby partial reflected some evidence but not
enough to comprehensively address the FDA regulatory standards. Most instruments provided partial evidence of
content validity. Input from clinicians and literature was common although few involved patients in both item
generation and cognitive debriefing. Construct validity was predominantly compromised by no evidence of a-priori
hypotheses of expected relationships. Evidence for test-retest reliability and internal consistency was available for
most PROs although few included complete results regarding all subscales and some failed to reach recommended
thresholds. The ability to detect change and interpretation of change were not investigated in most instruments
and no PROs had published evidence of a conceptual framework. The study concludes that none of the 26 have
the full evidence required by the FDA to support a label claim, and all require further research to support their use
as an endpoint. The Subjective Handicap of Epilepsy (SHE) and the Neurological Disorders Depression Inventory for
Epilepsy (NDDI-E) have the fewest gaps that would need to be addressed through additional research prior to any
FDA regulatory submission, although the NDDI-E was designed as a screening tool and is therefore unlikely to be
suitable as an instrument for capturing change in a clinical trial and the SHE lacks the conceptual focus on signs
and symptoms favoured by the FDA.
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Epilepsy is defined by the recurrence of spontaneous/un-
provoked seizures and covers a range of clinical situations
in terms of age of onset, type of seizures, aetiological back-
ground, resulting handicap, prognosis, and response to
treatment [1]. Epilepsies are a diverse group of disorders
with a complex classification, broadly categorised into
localization-related, generalized, undetermined, and spe-
cial syndromes [2]. Antiepileptic drugs (AEDs) are the
main treatment option; approximately 60% of newly diag-
nosed patients are seizure-free with AED monotherapy
and a further 10-20% with polytherapy [1,3]. Surgery offers
alternative treatment options for patients with medically
intractable epilepsy [4].
The assessment of efficacy in clinical studies evaluating
AEDs is generally focused on seizure frequency/occur-
rence in line with regulatory guidelines [1]. However there
is growing recognition of the value of capturing wider im-
pacts of treatments reported by patients in the form of pa-
tient reported outcomes (PROs) [5]. A PRO is defined as
any report of the status of a patient’s health condition that
comes directly from the patient without interpretation of
the patient’s response by a clinician or anyone else [5].
PROs take the form of carefully designed questionnaires
which can be used to capture and quantify the patient ex-
perience of treatment and treatment impacts. Given that
epilepsy is a complex disorder, which affects patients’ psy-
chological health, independence, emotional adjustment
and employment [6] there is a strong case for evaluating
the impact of AEDs on broader aspects of patient’s lives,
and previous studies have identified potential areas of pa-
tient’s lives that may be enhanced if epilepsy symptoms
were improved [7]. Therefore it is unsurprising that PROs
have been widely incorporated into clinical trials evaluat-
ing AEDs [8-10].
In order to guide the selection of PROs for epilepsy clin-
ical studies, there have been numerous reviews evaluating
PROs, each review with a unique focus: evaluating PROs
designed to measure change in seizure severity [11], over-
view of neuropsychological and behavioural measures
used AED clinical trials [8], guiding health-related quality
of life (HRQL) assessment in epilepsy [12], systematically
reviewing measures designed to assess the subjective im-
pact of epilepsy and treatment in children and adolescents
[13], guiding the selection and use of quality of life (QOL)
instruments in epilepsy [9], appraising the conceptual un-
derpinnings of paediatric QOL instruments [14], exploring
and reviewing PROs used to assess people with epilepsy
[10], and describing QOL instruments for children and
adolescents with neurodisabilities [15]. Similar reviews
were also conducted prior to 2000 [16,17].
Despite almost routine collection of PRO data in clinical
trials of AEDs and the wide choice of PRO instruments,
PRO results are not being routinely reported on EuropeanMedicines Agency (EMA) and Food and Drug Adminis-
tration (FDA) product labels. A review of the current state
of PRO label claims granted for new molecular entities ap-
proved 2006–2010 [18] found two approved for the treat-
ment of epilepsy had PRO label claims: VimpatW indicated
as adjunctive therapy for patients ≥17 years to treat partial
onset seizures and SabrilW indicated for refractory com-
plex partial seizures in adults. For both products the PRO
was a measure of seizure frequency. There are two likely
explanations for the lack of PRO label claims for epilepsy
treatments. The first relates to the possibility that there
may be a lag in the effect of AED treatment on PRO out-
comes after demonstration of positive treatment effect on
clinical efficacy outcomes e.g. seizure frequency/occur-
rence. Qualitative studies show that unpredictability of sei-
zures is a key factor in the impact of epilepsy for patients
[19-21]. Patients’ perception of the unpredictability of
their seizures may not change until sometime after a re-
duction in seizure frequency, or even seizure freedom is
achieved; 3–4 months, a common timescale for AED effi-
cacy trials, may be too short to expect much change in
PRO endpoints [11]. The second explanation, and the
focus of the current review, is the possibility that existing
PRO instruments do not meet regulatory requirements.
There is limited guidance from regulatory authorities on
incorporating PROs into evaluations of AEDs, the recent
EMA guideline on clinical investigation of medicinal prod-
ucts in the treatment of epileptic disorders [1] suggests that
a secondary efficacy variable could be ‘scales measuring so-
cial and working capacity, if validated’. Other than this the
authors could find no further guidance from either the
EMA or FDA specific to the use of PROs in epilepsy clin-
ical studies. For a PRO to be incorporated into a FDA or
EMA label claim, it is necessary for it to be developed to
standards required by the regulatory authorities [5,22].
Most of the epilepsy-specific PRO reviews conducted to
date were published prior to the current regulatory guid-
ance, and none have evaluated the extent to which PROs
have been developed to the standard required by regulatory
authorities. In order to guide those developing clinical stud-
ies to evaluate AEDs in selecting a PRO instrument for the
purpose of obtaining a PRO label claim, this review sought
to evaluate existing epilepsy-specific PRO instruments
against FDA regulatory standards and identify any gaps in
the development process that would need to be addressed
prior to regulatory review.
Methods
Literature search and PRO identification
Structured Embase and Medline searches were conducted
in February 2011 to identify epilepsy studies reporting the
use or development of PRO instruments in epilepsy sam-
ples. Searches were constructed by combining epilepsy
and seizure subject heading search terms with a number
Nixon et al. Health and Quality of Life Outcomes 2013, 11:38 Page 3 of 20
http://www.hqlo.com/content/11/1/38of PRO measurement terms. Searches were limited to
‘humans’, ‘English language’ and ‘year 2000 –current’. Full
search terms are shown in the Additional file 1.
Abstracts of publications identified by these searches
were screened to identify PRO instruments used. Full text
versions of publications were screened to identify specific
instruments where abstracts referred to PRO measurement
without naming a specific instrument, or where abstracts
specified endpoints that may have been captured by PRO
measurement. Further electronic searches were conducted
for each instrument identified to retrieve a copy of the in-
strument and establish its relevance. Given the wide variety
of PRO instruments used with epilepsy patients, the follow-
ing instrument inclusion criteria were used to focus the re-
view on broadly comparable instruments that might be
used to evaluate pharmacological treatment:
 Epilepsy-specific scale. Based on the FDA’s
preference for more proximal endpoints that are
specifically relevant to the target population, generic
PROs which make no reference to epilepsy were
excluded.
 Adult patient completed. Most epilepsy-specific
PROs have been developed for adult patient
completion. Scales developed to assess epilepsy
impacts for children are commonly designed for
proxy completion (e.g. by parents or clinical
assessors) in part or whole and are not directly
comparable to PROs designed for adult patient
completion. PROs designed for completion by
adolescent as well as adult patients were included.
 Target a concept that could potentially be impacted
by pharmacological treatment. Non-interventional
studies or those evaluating non-pharmacological
interventions may also use PROs to evaluate
concepts that would not be impacted by
pharmacological treatment. However, PROs
evaluating these concepts would not need to meet
FDA requirements for supporting a label claim.
Further literature searches were then conducted in
Embase and Medline to identify published validation work
on each PRO instrument identified. Full text versions of
all published reviews of PRO instruments identified by the
initial search and instrument focused literature searches
were retrieved and checked for any additional instruments
or validation work. Any instrument that was found to
comprise single items that did not form a scale and/or for
which no documentary evidence of validation could be lo-
cated was excluded from further review.
Developing the review criteria
Detailed review criteria were developed from require-
ments laid out in the FDA guidance for PROs supportinglabel claims [5]. These criteria are detailed in Table 1. De-
velopment work and evidence for psychometric properties
of each PRO instrument were extracted into structured in-
dividual instrument review tables before being systematic-
ally reviewed against the review criteria (Table 1).
Results
Identification of PROs
Initial Embase and Medline searches identified a total of
1854 publications (after de-duplication) from which 159
PRO instruments were identified by abstract or full-text
manuscript review. Following instrument retrieval and
initial review, 133 of these were excluded as they were
found to be not epilepsy specific (n = 52), not for adult
patient completion (n = 42), not to target a concept that
could be potentially impacted by pharmacological treat-
ment (n = 20) or instruments comprising single items
that did not form a scale and/or for which no documen-
tary evidence of validation could be located (n = 19).
Many of these instruments could be excluded on more
than one criterion. Numbers shown here depict the first
reason for exclusion.
PRO instrument characteristics
Twenty-six (26) epilepsy-specific PRO instruments were
identified and reviewed, Table 2 details the key character-
istics for each of these 26 instruments. The identified
PROs vary widely in their key characteristics. Conceptual
coverage of the PROs include instruments designed to
capture epilepsy attack experience including severity (e.g.
Attack Symptom Measure, Ictal Consciousness Inventory
(ICI), Liverpool Seizure Severity Scale (LSSS), Seizure Se-
verity Questionnaire (SSQ)); issues associated with the
treatment and management of epilepsy (e.g. Assessing
Side Effects of AED Treatment (SIDAED), Aldenkamp-
Baker Neuroassessment Schedule (ABNAS), Liverpool
Adverse Events Profile (LAEP), Portland Neurotoxicity
Scale (PNS), Epilepsy Self-Efficacy Scale (ESES)); instru-
ments designed to capture the impacts of epilepsy on dif-
ferent aspects of patient’s lives (e.g. Epilepsy Psycho-Social
Effects Scale, Impact of Epilepsy Questionnaire, Neuro-
logical Disorders Depression Inventory for Epilepsy
(NDDI-E), Perceived Stigma Scale, Washington Psycho-
social Seizure Inventory (WPSI)) and instruments measur-
ing the impact of epilepsy on patients’ HRQL (e.g.
Epilepsy Foundation of America (EFA) Concerns Index,
Epilepsy Surgery Inventory 55 (ESI-55), EPI-QOL, Quality
of Life in Epilepsy (QOLIE) instruments, Quality of Life in
Newly Diagnosed Epilepsy (NEWQOL)).
Instruments vary in terms of length, ranging from five
items (Perceived Limitations Scale) to 132 items (WPSI).
Nine of the PROs do not have a defined recall period (e.g.
ABNAS, SIDAED), two refer to the time of an epilepsy at-
tack (Attack Symptom Measure, ICI). Most specify a recall
Table 1 Review criteria based on FDA requirements for PROs to support label claims
Instrument
property




An explicit description or diagram of the relationships
between items in a PRO instrument and the concepts
measured, developed from empiric evidence to support
item grouping and scores.
✓ Published conceptual framework.
✘ No published conceptual framework.
Validity: Content
– Patient Input
Evidence that the instrument measures the concept of
interest including evidence from qualitative studies that
the items and domains of an instrument are appropriate
and comprehensive relative to its intended measurement
concept, population and use. Item generation should
include input from the target population.
✓ Patient involvement in concept elicitation/item
generation AND conduct of cognitive debrief with
patients.
Partial Some patient involvement in concept elicitation/item
generation or cognitive debrief but not both.





See Validity: Content (above). In addition to focus groups
and individual interviews with patients and family
members, PRO instrument items can be generated from
literature reviews, interviews with clinicians and other
sources.
✓ Use of literature to guide instrument/item development
OR involvement of clinical experts to guide instrument/
item development or evaluate content validity (not
necessary to have both).
✘ No use of literature to guide instrument/item
development AND no involvement of clinical experts to
guide instrument/item development or evaluate content
validity.
Validity: Construct Evidence that relationships among items, domains, and
concepts conform to a priori hypotheses concerning
logical relationships that should exist with other measures
(discriminant and convergent validity) or characteristics of
patients and patient groups (known groups validity).
✓ Clear hypotheses for relationships with measures (PRO or
clinical) of related concepts tested with hypothesised
relationships found (convergent validity). Can be
supported by evidence that measures of concepts that
should not be related show hypothesised lack of
correlation (discriminant validity). Can also be supported
by known groups validity (hypothesised, tested and
found) but known groups validity alone is not sufficient
evidence of construct validity.
Partial Construct validity tested without clear hypotheses OR
mixed results in terms of the extent to which observed
relationships match those hypothesised OR limited
number of tests undertaken i.e. if instrument is correlated
against one other PRO and that’s the extent of the
testing, then this is only partial evidence of construct
validity.
✘ Construct validity tested but observed relationships do
not match those hypothesised.
– Construct validity (convergent, discriminant and known
groups validity) not tested.
Reliability: Test-
retest
Stability of scores over time when no change is expected
in the concept of interest.
✓ Correlations ≥0.7 for all scores (including domain scores)
Partial Correlations for some scores <0.7 OR good test-retest
reliability found for total score but domain scores not
evaluated.
✘ Correlations <0.7 for all scores evaluated.
– Not tested for any scores.
Reliability: Internal
consistency
The extent to which items comprising a scale measure the
same concept, intercorrelation of items that contribute to
a score.
✓ Cronbach’s Alpha ≥0.8 for all scores (including domain
scores).
Partial Cronbach’s Alpha for some scores <0.8 OR good internal
consistency found for total score but domain scores not
evaluated.
✘ Cronbach’s Alpha <0.8 for all scores evaluated.
– Not tested for any scores.
✓
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Table 1 Review criteria based on FDA requirements for PROs to support label claims (Continued)
Ability to detect
change
Evidence that a PRO instrument can identify within person
changes over time in individuals or groups (similar to
those in clinical trials) who are known to have changed
with respect to the measurement concept.
Specific aim of analysis was to test within-group
responsiveness to change (e.g. set criteria for change e.g.
effect sizes), tested and met criteria for all scores
(including domain scores). Of key importance is clear
evidence/reason to believe that change has occurred in
a group (e.g. clinical outcome, anchor-based approach)
and that the PRO instrument scores detect this change.
Partial Within-group sensitivity to change criteria met for some
but not all scores OR criteria met for a total score but
responsiveness of domain scores not tested.
✘ Within group sensitivity to change tested but criteria not
met.
– Not tested for any scores. This includes claims of
instruments sensitivity to change based on between
group change (e.g. difference in change between
different arms of clinical trial) and observed change in a
group without clear evidence/reason to believe that
change has occurred in the group or without the clear
aim of evaluating sensitivity to change (e.g. observed
change from baseline within one arm of a clinical trial




The MID is the smallest change in score that can be
regarded as important [23]. The FDA guidance uses the
term ‘responder definition’ rather than MID to denote the
change in individual PRO score that indicates a treatment
benefit. Responder definitions are trial/treatment specific
and should be derived empirically using anchor-based
methods (clinical anchors or patient ratings of change).
Statistically derived responder definitions (e.g. distribution-
based methods commonly used to establish MID) can be
used to support anchor-based approaches but are not
appropriate as the sole basis for determining a responder
definition.
✓ Published values for interpretation of change for all
scores (including domain scores). Methodological details
about how values were derived e.g. statistically, using
anchor-based methods, provided and discussed in
results text.
Partial Values for interpretation of change for total score but
not domain scores. Methodological details about how
this was derived e.g. statistically, using anchor-based
methods, provided and discussed in results text.
– No published evidence for interpretation of change.
Glossary of Terms:
Cognitive debrief: a qualitative research tool used to determine whether concepts and items are understood by patients in the same way that instrument
developers intend.
Concept: the specific measurement goal (i.e. the thing that is to be measured by the PRO instrument).
Item: an individual question, statement or task (and its standardized response options) that is evaluated by the patient to address a particular concept.
Reliability: the ability of a PRO instrument to yield consistent, reproducible estimates of true treatment effect.
Responder definition: a score change in a measure, experienced by an individual patient over a predetermined time period that has been demonstrated in the
target population to have significant treatment benefit.
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with five PROs referring to multiple recall periods within
the same PRO (e.g. EPI-QOL, NEWQOL, SHE). Response
options for most of the reviewed PROs employ a Likert
approach with 3–5 options, for example the Epilepsy
Psycho-Social Effects Scale has a five point Likert scale
ranging from ‘almost always or always’ to ‘never’ and the
EPI-QOL has a five point response scale ranging from
‘very frequently’ to ‘not at all’. Less common is a numerical
rating scale (NRS) approach with anchors, such as the
ESES which has a 11 point scale ranging from 0 (I cannot
do at all) to 10 (sure I can do).
The PROs provide different levels of information de-
pending on the scoring approach, a minority of instru-
ments provide only a total score based on the scoring of
all items in the PRO (e.g. EFA Concerns Index, NDDI-E
), whilst most provide a more detailed amount of infor-
mation through provision of sub-scale scores (alsoreferred to as domain scores), with the number of sub-
scale scores ranging widely, from two (e.g. ICI, PNS) to
20 (Bonner Psychsoziale Skale fur Epilepsie (BPSE)).
Most instruments provide between 5–15 subscale
scores.
PRO review against regulatory requirements
Table 3 provides the results of the PRO review against
the regulatory requirements detailed in Table 1.
Conceptual framework
The authors did not find any published conceptual
framework for any of the reviewed instruments.
Content validity
Three of the PROs involved patients in concept elicit-
ation/item generation and in the evaluation of items
through a cognitive debrief methodology or similar
Table 2 Epilepsy-specific PRO instruments
Abbreviated
name
















An instrument to measure patient
perceived cognitive side effects of AED
treatment.




Four point scale ranging from ‘no










An instrument to measure ictal
symptoms that would typically be
associated with panic disorder.




Two options indicating the absence or




2. Chest and abdomen
symptoms







A self-report questionnaire designed to
evaluate the patient’s areas of illness-
related psychosocial problems and
cognitive-behavioural variables.





Analogue ratings of between 0 to 6.
Scales include Never to Always or Not
at all to Extremely and primarily focus
on frequency of cognitions or
behaviour
[30]
1. Impairment to daily life
a. Physically
b. Activity/capability























































A HRQL measure for patients with
epilepsy, covering concerns relating to
affective enjoyment, general autonomy,
seizure recurrence, family burden and
lack of understanding.
Ratings are summed to
produce a Concerns Index
Score.
20 Past 4 weeks Five point scales ranging from ‘not at all
concerned’ to ‘extremely concerned’ or





An instrument to determine the social
effects of epilepsy and measure
psychosocial functioning.




Five point scale ranging from ‘almost
always or always’ to ‘never’
[34]
1. Attitude towards accepting
attacks
2. Fear of having seizures
3. Fear of stigma in
employment
4. Lack of confidence about
the future
5. Lack of confidence about
travelling
6. Adverse reaction on social
life
7. Adverse reaction on leisure
pursuits

























Table 2 Epilepsy-specific PRO instruments (Continued)
9. Difficulty communicating
with the family
10. Problems with taking
medication
11. Distrust of the medical
profession
12. Depression or emotional
reactions
13. Feeling of increased social
isolation
14. Lethargy/lack of energy
- EPI-QOL A HRQL assessment instrument for
adults with epilepsy.





Five point scale ranging from ‘very










An instrument to measure self-efficacy
in regards to epilepsy management.
Total score. 33 No recall
period
Ten point scale ranging from ‘I cannot




An instrument to measure HRQL in
epilepsy surgery patients.
Weighted total score, three
composite scores (Physical,
mental and cognitive role)





Various response formats. (‘strongly
agree’ to strongly disagree’, ‘often’ to
‘not at all’, yes/no)
[38,39]
1. Emotional wellbeing



































Table 2 Epilepsy-specific PRO instruments (Continued)




A quantitative assessment of the level of
awareness and content of ictal
consciousness.
Two sub-scale scores: 20 During a
single seizure
Three point scale: ‘no’; ‘yes, a bit (yes,
vaguely)’; ‘yes, much (yes, clearly)’.
[40]
1. Level of consciousness
(ICI-L)




Developed to assess the impact of
epilepsy and antiepileptic drug therapy
on an individual’s relationship with
friends and family, social life,
employment, health, self-esteem, plans
for the future, and standard of living.
Total impact score. 8 No recall
period.





An instrument to measure total side
effects burden of a medical regimen. It
was developed to evaluate the most
common negative side effects reported
by patients taking AEDs. The AEP
evaluates the interiactal state. It's widely
used alone and is also part of the
Liverpool Battery.
Total score. 19 Past 4 weeks Four point scale ranging from ‘never a









A scale designed to quantify patient’s
own perceptions of seizure severity.
Weighted most severe ictal
effects score.
12 Past 4 weeks Various scales referring to the content
of each question ranging from 4 to 6
options. For example ‘I always feel







An instrument to detect depression in
epilepsy patients.
Total score. 6 Past two
weeks
Four point frequency scale ranging from
‘always or often’ to ‘never’.
[54]
NEWQOL Quality of Life in
Newly Diagnosed
Epilepsy
An instrument to measure aspects of
quality of life postulated as being
important for patients recently
diagnosed with epilepsy.






Various response formats including 4
and 5 point scales ranging from ‘no
problem’ to ‘a serious problem’ or


















































A measure of the constraints that
patients with epilepsy might experience
including the sense of vulnerability to
the physical consequences of seizures.
Total score. 5 No recall
period
Four point scale ranging from ‘strongly




A measure of the extent to which
people with epilepsy feel they are
victims to prejudice, including the
extent to which individuals are treated
differently and inability to change the
views of others.
Total score. 6 No recall
period
Four point scale ranging from ‘strongly








A test-battery for assessing the severity
of epilepsy, epilepsy related quality of
life, restrictions in daily life and
psychosocial problems.
Separate scores for each
instrument in the battery:
69 Various recall
periods
Various response options [56]
1. Restrictions in daily life^
2. Epilepsy related fear$
3. Stigma
4. Emotional adaptation
5. Problems at work
6. Problems at school




An instrument to measure commonly
experienced adverse events associated
with AEDs.
































Table 2 Epilepsy-specific PRO instruments (Continued)
QOLIE-10 Quality of life in
epilepsy 10
A brief measure of overall quality of life
for patients with epilepsy.
Total score and three
subscale scores:
10 Past 4 weeks Various 5 point scales including ‘not at







calculated for the 7 domains
of the QOLIE-31, although for
the QOLIE-10, 5 of the 7
subscales are scored from
single items.
QOLIE-31 Quality of life in
epilepsy 31
Overall quality of life for patients with
epilepsy.
Total weighted score and
seven subscale scores:
31 Past 4 weeks Various response formats including five
and six point scales ranging from ‘very
fearful’ to ‘not fearful at all’ or all the
time’ to ‘none of the time’
[44,59-63]
1. Seizure worry






QOLIE-89 Quality of life in
epilepsy 89
Overall quality of life for patients with
epilepsy
Total weighted score and 17
subscale scores:
89 Past 4 weeks Various response formats including yes/
no or 5 point scales ranging from
‘excellent’ to ‘poor’ or ‘all the time’ to












11. role limitations: emotional






























SEALS Side Effect and
Life Satisfaction
Inventory
A self-report questionnaire designed to
measure satisfaction with AED therapy.
Total score and five subscale
scores:











Measures patient’s subjective handicap
of epilepsy based on the WHO concept
of handicap. It is recommended for use
in studying the long-term consequences
of medical, psychosocial and surgical
interventions in epilepsy.







Various 5 point scales. For example,
‘Much better’ to ‘Much worse’ or ‘Very
often’ to ‘never’.
[72]














An instrument to assess the duration
and severity of adverse events that are
possibly AED related.
Total score. 46 No recall
period
Four point severity scale ranging from
‘no problem’ to ‘serious problem’ and a
three point duration scale ranging from
‘since a few weeks’ to ‘half a year or
longer’.
[73-77]
Adverse events can also be





































Table 2 Epilepsy-specific PRO instruments (Continued)
SSQ Seizure Severity
Questionnaire
An instrument designed to assess
seizure severity as a treatment response.
The measure asks about events before,
during and after a seizure and covers
bother, severity and frequency of
seizures.
Three subscale scores: 22 Past 4 weeks Various response formats. Format is
primarily seven point scales referring to
frequency, ranging from ‘never’ to
‘always’, bother, ranging from ‘no
bother at all’ to ‘very bothersome’ and
severity ‘very mild’ to ‘very severe’,









Provides absolute and relative estimates
of psychosocial functioning.
Eight subscale scores: 132 No recall
period
Yes/no responses reflecting self-











*Stigma of epilepsy scale has been used as a stand-alone PRO instrument to measure epilepsy patient’s perception of stigma. It comprises 3 items forming a total score [81-84].
^ Restrictions in daily life has been used as a stand-alone PRO instrument to measure social, physical and psychological dimensions that are generally stressed as central aspects of HRQL. It comprises 11 items
representing three sub-scales: independent living and mobility, physical and emotional health, partnership, family and friends [56].
$ Epilepsy Related Fears has been used as a stand-alone PRO instrument to measure fears regarding aspects of physical and social consequences. Comprising 11 items representing two sub-scales: Physical
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and SHE also had documented evidence that literature
had been used to guide the instrument development
and/or clinical experts were involved. Most of the PROs
(n = 14) had partially involved patients in the develop-
ment of the instrument, in most cases either concept
elicitation OR cognitive debrief were undertaken, but
not both methodologies. All but one of these 14 instru-
ments (LAEP) had also reviewed literature and/or in-
volved clinical experts in the instrument development.
Of the 26 instruments only five did not involve literature
and/or clinical experts in the instrument development
process according to published information.
Construct validity
Seven instruments had full evidence of the construct val-
idity of the PRO by providing hypotheses of the
expected relationships between the PRO under evalu-
ation and other clinical or PRO measures, and the hy-
potheses being supported by reported results. Most of
the PROs only had partial evidence of construct validity
(n = 16), in most cases there was no evidence of hypoth-
eses of expected relationships being developed in ad-
vance of analysis. For some instruments this was
compounded by limited testing e.g. only known groups
validity was evaluated or very limited comparisons were
made. The Perceived Limitations Scale, Perceived Stigma
Scale and SIDAED did not have any available evidence
of construct validity.
Reliability
Five PROs had sufficient evidence of test-retest reliability,
and four PROs had sufficient evidence of internal
consistency reliability, with two PROs providing sufficient
evidence of both types of reliability: LAEP and NDDI-E.
Thirteen PROs had partial evidence of test-retest reliabil-
ity and 14 had partial evidence of internal consistency.
Most of the PROs that had only partial evidence of these
measurement properties had a mix of results for sub-
scales in terms of achieving the required criteria (i.e. α ≥
0.8 for internal consistency [85,86], r ≥ 0.7 for test-retest
reliability) (e.g. PESOS, EPI-QOL) or there were no results
provided for the PROs total score (e.g. Attack Symptom
Measure). Eight PROs had no evidence of test-retest reli-
ability (Attack Symptoms Measure, BPSE, ESI-55, ICI, Im-
pact of Epilepsy scale (IES), Perceived Limitations Scale,
Perceived Stigma Scale and SIDEAD) and four instru-
ments had no evidence of internal consistency reliability
(Epilepsy Psycho-Social Effects Scale, Portland Neurotox-
icity Scale, SIDAED and SSQ).
Four PROs had evidence of testing for internal
consistency but failed to reach the required standard of
α ≥ 0.8 for all reported scales including any total score:
Quality of Life in Epilepsy 10 (QOLIE 10), PerceivedStigma Scale, Perceived Limitations Scale and IES. The
IES has an internal consistency of 0.65 which increases
to 0.82 if one of the 8 items is removed, but later publi-
cations are based on either the eight item version or a
10-item version [42,87] for which no published psycho-
metric validation evidence could be found. The Per-
ceived Limitations Scale had a notably low internal
consistency (α = 0.55) with the Perceived Stigma Scale
getting close to the required standard (α = 0.75) [55].
The reported alpha values for the three empirically de-
rived factors from the QOLIE-10 (epilepsy effects, men-
tal health scale, role function) do not meet the criterion
thresholds [58]. These three subscales are not the usual
scores derived from the QOLIE-10. Researchers more
commonly report the same seven subscales as the
QOLIE-31 (five of which have only one item in the
QOLIE-10) and/or a total QOLIE-10 score [59,88,89] for
which no evaluation of internal consistency has been
published.
Ability to detect change
Four PROs had full evidence of ability to detect change
and reported the results of analysis undertaken with the
specific aim of testing within-group responsiveness for
all sub-scales as well as total score (as appropriate): ESI-
55, Performance, subjective evaluation and socio-
demographic data (PESOS), Quality of Life in Epilepsy
31 (QOLIE-31) and Quality of Life in Epilepsy 89
(QOLIE-89). Three PROs provided partial evidence of
ability to detect change: LSSS, QOLIE-10 and WPSI; for
example analysis was conducted on a previous version of
the PRO (LSSS) or a non-empirically derived scale struc-
ture (QOLIE-10 results based on sub-scales taken from
the QOLIE-31). For most of the PROs (n = 19) this
measurement property had not been investigated.
Interpretation of change
The LAEP was the only PRO that had fully documented
evidence of the minimally important difference (MID) of
the scale. This was evaluated in a study that was designed
to assess the magnitude of change in the LAEP and other
PROs in order to exclude chance or error at various levels
of certainty in patients with medically refractory epilepsy
through application of a Reliable Change Index analytic
approach [44]. Two PROs had partial evidence of MID;
the MID investigation for the QOLIE-31 provided evi-
dence for the total score but none of the sub-scales and
for the QOLIE-89 results were provided for selected sub-
scales and total score. No anchor-based values for
interpreting change were reported for any of the reviewed
instruments, and none reported responder definitions for
an epilepsy population according to the FDA’s require-
ments around establishing responder definitions (see
Table 1).





















ABNAS ✘ Partial ✓ Partial Partial Partial - -
Attack Symptom
Measure
✘ ✘ ✓ Partial - Partial - -
BPSE ✘ ✘ ✓ Partial - Partial - -
EFA ✘ ✓ ✘ Partial ✓ Partial - -
EPSES ✘ Partial ✓ Partial Partial - - -
EPI-QOL ✘ Partial ✓ ✓ Partial Partial - -
ESES ✘ Partial Partial Partial Partial ✓ - -
ESI-55 ✘ Partial ✓ ✓ - Partial ✓ -
ICI ✘ Partial ✓ ✓ - ✓ - -
IES ✘ Partial ✓ ✓ - ✘ - -
LAEP ✘ Partial ✘ Partial ✓ ✓ - ✓
LSSS ✘ ✓ ✓ Partial Partial Partial Partial -
NDDI-E ✘ ✘ ✓ ✓ ✓ ✓ - -
NEWQOL ✘ Partial ✓ Partial Partial Partial - -
Perceived Limitations
Scale
✘ ✘ ✘ - - ✘ - -
Perceived Stigma Scale ✘ ✘ ✘ - - ✘ - -
PESOS ✘ ✘ ✓ Partial Partial Partial ✓ -
PNS ✘ ✘ ✓ Partial ✓ - - -
QOLIE-10 ✘ Partial ✓ Partial Partial ✘ Partial -
QOLIE-31 ✘ Partial ✓ Partial Partial Partial ✓ Partial
QOLIE-89 ✘ Partial ✓ Partial Partial Partial ✓ Partial
SEALS ✘ Partial ✓ ✓ Partial Partial - -
SHE ✘ ✓ ✓ ✓ ✓ Partial - -
SIDAED ✘ ✘ ✘ - - - - -
SSQ ✘ Partial ✓ Partial Partial - - -
WPSI ✘ ✘ ✓ Partial Partial Partial Partial -
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This review sought to evaluate epilepsy-specific PRO in-
struments against FDA regulatory standards and to iden-
tify gaps in the development process of the instruments
that would need to be addressed prior to regulatory re-
view. Twenty-six (26) epilepsy-specific PRO instruments
were identified and reviewed.
This review identified that the SHE and NDDI-E met
more of the regulatory requirements in terms of measure-
ment properties, with both scales meeting four of the eight
measurement properties evaluated. These two PROs lacked
a published conceptual framework and require further evi-
dence of ability to detect change and interpretation of
change. In addition, the NDDI-E requires further evidence
of patient input and the SHE requires further evidence of
internal consistency reliability. Internal consistency fellbelow the required standard (α ≥0.8) [85] for some of the
SHE’s sub-scales, further developmental work might be
needed to increase the internal consistency of this scale
(e.g. item removal, development of supplemental items,
item re-wording, revised scale structure/conceptual frame-
work). The SHE and NDDI-E were designed for different
purposes. The SHE is a measure of patient’s subjective
handicap of epilepsy based on the World Health Organisa-
tion (WHO) concept of handicap, providing six subscale
scores: work and activities; social and personal; physical;
self-perception; life satisfaction; and change. The lack of
focus on signs and symptoms in the SHE is likely to make
it unfavourable from the FDA perspective as an instrument
to support a PRO label claim. The same is true of other
PROs evaluated in this review. The NDDI-E is a short in-
strument designed to detect depression in epilepsy patients,
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as an outcome measure in clinical trials [90,91], this may
have been inappropriate as it was designed as a screening
tool, and therefore its ability to detect change is not only
unknown but potentially unlikely given that it was not
designed to capture change.
The LAEP, ICI and ESI-55 all met requirements for three
of the eight measurement properties. The LAEP in terms of
test-retest reliability, internal consistency and interpretation
of change; the ICI in terms of literature and clinician input,
construct validity and internal consistency; and the ESI-55
in terms of literature and clinician input, construct validity
and ability to detect change. Therefore all three instruments
lack a published conceptual framework and required fur-
ther evidence in terms of patient input, as well as specific
gaps for each PRO.
When considering PROs with at least partial evidence of
measurement properties, a different group of PROs come
to the forefront: the QOLIE-31 and QOLIE-89 met or par-
tially met requirements for seven out of the eight measure-
ment properties, and the LSSS met or partially met
requirements for six of the measurement properties. How-
ever, of concern for the QOLIE-89 is that seizure free pa-
tients did not score significantly higher than the most
severe group on nine of the sub-scales [64] and test-retest
reliability was <0.7 for four of the sub-scales [64]. Of con-
cern for the QOLIE-31 is that internal consistency was <0.8
for four sub-scales [60] (although at 0.77-0.79 they were
very close to this threshold) and test-retest fell below 0.7
for one sub-scale [60]. Questions are raised over the LSSS
because of gaps in the evidence for reliability and validity.
Of particular concern from a regulatory perspective
are the Perceived Limitations Scale, Perceived Stigma
Scale and the SIDAED, all of which failed to achieve
even partial evidence for any of the eight measurement
characteristics. Notably, the Perceived Limitations Scale
and Perceived Stigma Scale failed to achieve required
standards for internal consistency when tested (no evi-
dence of testing for this for the SIDAED). No other psy-
chometric properties were tested for these three PROs.
Content validity is defined by the FDA as ‘. . . the extent
to which the instrument measures the concept of interest’,
with evidence being supported through the conduct of
qualitative studies to demonstrate that the items and do-
mains of an instrument are appropriate and comprehensive
relative to its intended measurement concept, population
and use [5]. Importantly, whilst all the evidence criteria in
this review are considered to be required by the FDA
(with the exception of responder definitions which are
recommended) the FDA make a clear statement that ‘It is
important to establish content validity before other meas-
urement properties are evaluated’. The FDA will review the
process for evidence of content validity in terms of item
generation, data collection method and instrumentadministration mode, recall period, response options, in-
strument format, instructions and training, patient under-
standing, scoring of items and domains, and respondent
and administration burden. The evaluation of content valid-
ity in this review has been an assessment of process rather
than an evaluation of the evidence for content validity, with
access restricted to published information rather than the
detailed qualitative results that would be required for FDA
assessment of content validity. No published conceptual
framework was identified for any of the instruments; how-
ever for nearly all of the reviewed PROs there is sufficient
information regarding how items group into domains/con-
cepts to be able to develop a conceptual framework. Com-
pared to other deficiencies, this may not be hard to
overcome. Providing empirical evidence in support of the
conceptual framework, would be a greater challenge.
In terms of evidence gathered through psychometric test-
ing, the review identified common pitfalls. In relation to
testing for construct validity, the FDA require that a priori
hypotheses are tested concerning logical relationships that
should exist with measures of related concepts or scores.
This was an area where most PROs failed to meet the cri-
teria in this review. It is entirely possible that hypotheses
were set in advance of analysis, but not reported in the pub-
lished manuscript and it is strongly encouraged that this
information is shared in publications reporting the psycho-
metric properties of PROs. In terms of test-retest reliability
and internal consistency, it is necessary to provide evidence
for all domains and total scores (if applicable). Again this
was a common area where PROs failed to meet the criteria
in this review.
Although several PROs had evidence from clinical stud-
ies that the PRO measured change in an epilepsy popula-
tion, few PROs had evidence that ability to detect change
had been specifically investigated. One likely reason for
this is that this measurement property is harder to evalu-
ate in terms of study design as it means undertaking a lon-
gitudinal study of a patient group expected to improve/
deteriorate. However, this is an essential measurement
property, particularly when considering that the PROs are
to be incorporated into clinical studies designed to test
the effectiveness of a treatment for epilepsy.
Even fewer PROs had evidence for interpreting change
or empirically derived responder definitions. The re-
sponder definition may vary by target population or
other clinical trial design characteristics and therefore
the FDA will evaluate a PROs responder definition in
the context of each clinical trial. Evidence towards a
PROs MID can contribute to the responder definition,
and so this review sought to identify any evidence of sta-
tistically derived or anchor-based MID and/or responder
definition, and found that only the LAEP was able to
demonstrate empirically derived evidence of the meas-
urement property.
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this review is that of several versions of one PRO instru-
ment. Great care has to be taken when evaluating pub-
lished evidence on the development and psychometric
validation of a PRO instrument that the same version of
the PRO is being referred to. By way of example, the
ESES was originally developed to be a 25-item instru-
ment, with evidence for content validity, construct valid-
ity and internal consistency [24]. However, the ESES was
later updated to include an additional eight items to fur-
ther assess self-efficacy associated with lifestyle issues
with limited details around this update being published.
In these instances, the evidence provided for earlier ver-
sions of the instrument were considered ‘partial’ evi-
dence in Table 3 as this earlier evidence is likely to
indicate how the revised instrument might perform.
However, from a regulatory perspective the FDA would
need to see full evidence for the developmental history
and measurement properties of the revised instrument,
assuming it is the revised version that is currently avail-
able for use in clinical trials.
It is vital to consider these findings in the broader con-
text of PRO label claims in the US. The review of the
current state of PRO label claims granted for new molecu-
lar entities approved 2006–2010 [18] found that of 116
products identified, 24% were granted PRO claims of
which 86% were for symptoms and of these 38% were pain
related. The proportion of new molecular entities and bio-
logic license applications with PRO label claims has de-
creased slightly from 30% 1997–2002 to 24% 2006–2010.
PRO label claims for non-primary endpoints were uncom-
mon, with occurrence of symptoms the mostly commonly
reported PRO label claim granted. The majority of ac-
cepted claims were supported by simple scales such as vis-
ual analogue scale (VAS), numeric rating scale (NRS), or
symptom diaries, or on the basis of measures that have
been traditionally accepted by the reviewing divisions.
Within this context none of the reviewed epilepsy instru-
ments are ‘simple scales’ i.e. VAS, NRS or symptom diar-
ies. The reviewed PRO instruments do not appear to be
measures that are ‘traditionally accepted by the reviewing
divisions’ as none were identified in labels for PRO epi-
lepsy treatments approved 2006–2010. The level of evi-
dence required to support a desired label claim on the
basis of the reviewed PRO instruments is of substantial
importance as the reviewed instruments are not the typ-
ical PRO instruments being seen to support NME and
BLA product approvals in the US.
It is worth considering the extent to which the evaluated
PROs would be suitable to support regulatory approval of
medicines in Europe through a regulatory review
conducted by the EMA. The EMA has been less prescrip-
tive in terms of their requirements for PROs, with one re-
flection paper published in 2005 for HRQL instruments,but nothing extended more generally to PROs. In the ab-
sence of clear guidelines from the EMA, it is difficult to
determine which of the evaluated PROs would be well re-
ceived by the EMA. However, whilst both the FDA and
EMA require PROs supporting regulatory approvals to be
validated and reliable, the EMA is more likely to accept
and encourage the use of well-known, commonly used
PROs than the FDA. The EMA also places less emphasis
on qualitative evidence of content validity. Therefore
PROs that are likely to be well received by the EMA will
need to have demonstrated evidence of the psychometric
properties of the PROs, particularly where this evidence is
published in peer-review publication.
A limitation to this research is that the review was
conducted on published information. It is frequently the
case that documentation on the development process for
PRO instruments is not published, particularly for older
PRO instruments which were developed at a time where
there were less publication options for PRO develop-
ment manuscripts. It is likely that there are more details
on the development of the reviewed instruments that
have not been considered in this review. An important
step for anyone considering the use of the PRO to sup-
port a label claim is to contact the instrument developer
to see if further information can be made available to ad-
dress seeming gaps in the evidence, which if available
will reduce the need to conduct further research to
gather evidence in support of the PRO instrument.
Conclusions
This systematic review of 26 epilepsy-specific PRO instru-
ments, evaluated to the standards set out in the FDA guid-
ance [5] indicates that none of the identified instruments
have the full evidence required by the FDA to support the
label claim, and all require further research to support
their use as an endpoint. This may at least partially explain
the lack of PRO label claims in support of epilepsy prod-
ucts. The SHE and NDDI-E have the fewest gaps that
would need to be addressed through additional research
prior to any FDA regulatory submission, although the
NDDI-E was designed as a screening tool and is therefore
unlikely to be suitable as an instrument for capturing
change in a clinical trial and the SHE lacks the conceptual
focus on signs and symptoms favoured by the FDA.
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